Jonathan Rigby is an experienced CEO with three decades of experience creating value and opportunities for companies in the pharmaceutical, biotech, and drug-delivery technology industries. He currently serves as the CEO of Revolo Biotherapeutics, a biotechnology company setting out to revolutionize the treatment for autoimmune and allergic diseases through the development of therapies that reset the immune system to achieve superior long-term disease remission. He holds a Bachelor of Science Degree with Honors in biological sciences from Sheffield University, U.K., and an MBA from Portsmouth University, U.K.